SLAM
DFTX

Swiss Life Asset Management’s Definium Therapeutics DFTX Stock Holding History

Swiss Life Asset Management’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$187K Buy
+17,745
New +$301K ﹤0.01% 1402

Other funds holding DFTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Swiss Life Asset Management's DFTX Position: Q1 2026 in Review

Swiss Life Asset Management opened a new position in Definium Therapeutics (DFTX) in Q1 2026: 17,745 shares worth $187K. The stake represents ﹤0.01% of the portfolio and ranks #1402 among its holdings.

247 funds tracked by Wall St. Rank hold DFTX as of Q1 2026.

  • Swiss Life Asset Management held 17,745 shares of Definium Therapeutics worth $187K as of Q1 2026.
  • Definium Therapeutics was a new Swiss Life Asset Management position in Q1 2026.
  • Definium Therapeutics made up ﹤0.01% of Swiss Life Asset Management's portfolio in Q1 2026, its #1402 holding.
  • 247 funds tracked by Wall St. Rank held Definium Therapeutics as of Q1 2026.

Based on Swiss Life Asset Management's 13F filing for Q1 2026, filed 14 May 2026.